220 related articles for article (PubMed ID: 33552659)
1. Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia.
Garner LM; Kline T; Miller J; Deal A; Zhu A; Sketch MR; Coombs CC; Muluneh B
J Adv Pract Oncol; 2021; 12(1):20-28. PubMed ID: 33552659
[TBL] [Abstract][Full Text] [Related]
2. Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.
Lu X; Emond B; Morrison L; Kinkead F; Lefebvre P; Lafeuille MH; Khan W; Wu LH; Qureshi ZP; Jacobs R
Patient Prefer Adherence; 2023; 17():2073-2084. PubMed ID: 37641660
[TBL] [Abstract][Full Text] [Related]
3. Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study.
Moldovianu AM; Stoia R; Vasilica M; Ursuleac I; Badelita SN; Tomescu AA; Preda OD; Bardas A; Cirstea M; Coriu D
Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837525
[No Abstract] [Full Text] [Related]
4. Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia.
Collins J; Stump SE; Heiling H; Muir M; Deal A; Proco D; Nguyen C; Cozad M; Mato A; Coombs CC; Muluneh B
Leuk Lymphoma; 2022 Aug; 63(8):1823-1830. PubMed ID: 35249442
[TBL] [Abstract][Full Text] [Related]
5. Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Barrientos JC; Ayed AO; Cha A; Du S; Fang B; Hall R; Marks SM; Peng E; Rhodes JM; Ryan K; Winters SB; Yeung PL; Hou JZ
Target Oncol; 2023 Sep; 18(5):727-734. PubMed ID: 37728835
[TBL] [Abstract][Full Text] [Related]
6. Real-world experience of ibrutinib therapy in relapsed chronic lymphocytic leukemia: results of a single-center retrospective analysis.
Nuttall E; Tung J; Trounce E; Johnston R; Chevassut T
J Blood Med; 2019; 10():199-208. PubMed ID: 31372077
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib Dose Adherence and Therapeutic Efficacy in Non-Hodgkin Lymphoma: A Single-Center Experience.
Williams AM; Baran AM; Casulo C; Reagan P; Friedberg JW; Helber M; Moore J; Baloga E; Zent CS; Barr PM
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):41-47. PubMed ID: 30409718
[TBL] [Abstract][Full Text] [Related]
8. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
[TBL] [Abstract][Full Text] [Related]
9. Real-world Prescription Pattern, Discontinuation and Costs of Ibrutinib-Naïve Patients with Chronic Lymphocytic Leukemia: An Italian Healthcare Administrative Database Analysis.
Ronconi G; Dondi L; Calabria S; Piccinni C; Pedrini A; Esposito I; Martini N
Clin Drug Investig; 2021 Jul; 41(7):595-604. PubMed ID: 34032988
[TBL] [Abstract][Full Text] [Related]
10. Use of Ibrutinib in 10 Patients with Treatment-Naïve or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Real-World Clinical Practice -A Report from a Single Medical Institution.
Sekiguchi Y; Iizuka H; Takizawa H; Mitsumori T; Tomita S; Izumi H; Okubo M; Miyake K; Osawa T; Sawada T; Yoshikawa S; Noguchi M
Gan To Kagaku Ryoho; 2021 Jul; 48(7):921-926. PubMed ID: 34267029
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib.
Jain P; Thompson PA; Keating M; Estrov Z; Ferrajoli A; Jain N; Kantarjian H; Burger JA; O'Brien S; Wierda WG
Cancer; 2017 Jun; 123(12):2268-2273. PubMed ID: 28171709
[TBL] [Abstract][Full Text] [Related]
12. Ibrutinib for treatment of chronic lymphocytic leukemia.
Vela CM; McBride A; Jaglowski SM; Andritsos LA
Am J Health Syst Pharm; 2016 Mar; 73(6):367-75. PubMed ID: 26953281
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
14. Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.
Byrd JC; Furman RR; Coutre SE; Flinn IW; Burger JA; Blum K; Sharman JP; Wierda W; Zhao W; Heerema NA; Luan Y; Liu EA; Dean JP; O'Brien S
Clin Cancer Res; 2020 Aug; 26(15):3918-3927. PubMed ID: 32209572
[TBL] [Abstract][Full Text] [Related]
15. Real-world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the UK.
Hillmen P; Xie J; Yong ASM; Waweru C; Sorof TA; Goyal RK; Davis KL
EJHaem; 2021 May; 2(2):219-227. PubMed ID: 35845284
[TBL] [Abstract][Full Text] [Related]
16. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
17. Ibrutinib discontinuation in patients with relapsed or refractory chronic lymphocytic leukemia treated in a compassionate use program: A report from the Polish Adult Leukemia Study Group (PALG).
Iskierka-Jażdżewska E; Puła B; Szeremet A; Hus M; Gołos A; Hołojda J; Piszczek W; Steckiewicz P; Wojciechowska M; Zaucha JM; Warzocha K; Jamroziak K
Adv Clin Exp Med; 2019 Aug; 28(8):1051-1057. PubMed ID: 31199879
[TBL] [Abstract][Full Text] [Related]
18. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
[TBL] [Abstract][Full Text] [Related]
19. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Barr PM; Brown JR; Hillmen P; O'Brien S; Barrientos JC; Reddy NM; Coutre S; Mulligan SP; Jaeger U; Furman RR; Cymbalista F; Montillo M; Dearden C; Robak T; Moreno C; Pagel JM; Burger JA; Suzuki S; Sukbuntherng J; Cole G; James DF; Byrd JC
Blood; 2017 May; 129(19):2612-2615. PubMed ID: 28373262
[TBL] [Abstract][Full Text] [Related]
20. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Awan FT; Schuh A; Brown JR; Furman RR; Pagel JM; Hillmen P; Stephens DM; Woyach J; Bibikova E; Charuworn P; Frigault MM; Hamdy A; Izumi R; Linghu B; Patel P; Wang MH; Byrd JC
Blood Adv; 2019 May; 3(9):1553-1562. PubMed ID: 31088809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
